Introduction and results
The utility of viral vector-mediated gene transfer has been demonstrated in experimental models of cerebral ischemia and currently provides a promising therapeutic approach. 1 Gene transfer of several proteins (including neurotrophic factors, antiapoptotic proteins, heat shock proteins, anti-inflammatory mediators) in cerebral ischemia models have been shown to confer neuroprotection. Cerebral ischemia induces a complex series of molecular pathways involving signaling mechanisms, gene transcription and protein formation. We and others have demonstrated that increased protease activity in the extracellular matrix, which results from the activation of matrix metalloproteinase (MMPs), plays a critical role in contributing to the neuronal damage that occurs after global and focal cerebral ischemia. [2] [3] [4] Pharmacological inhibition of MMPs or MMP-9 gene knockout significantly reduces proteolytic activity and tissue damage after cerebral ischemia in animal models. 3, 4 In vivo, MMP activity is tightly controlled by endogenous tissue inhibitors of MMPs (TIMPs), a family of glycosylated proteins, comprising four members (TIMP-1-4), which inhibit multiple MMPs and display different interactions and substrate specificity with MMPs proenzymes. 5, 6 TIMPs also possess distinct biological functions that are independent of their ability to inhibit MMPs and include the capacity to activate intracellular signaling pathways and effect processes like cellular differentiation and proliferation. 7, 8 Thus, elevation of TIMP expression might reduce ischemic damage by modulating exaggerated MMP activity or activating potentially neuroprotective signal-transduction pathways. In hippocampal neuronal cultures, adenovirus-mediated overexpression of TIMP-1 has been shown to protect against glutamateinduced excitotoxicity. 9 However, for gene transfer of TIMP to be clinically relevant, we need to determine whether overexpression of TIMPs is efficient after adenoviral-mediated delivery and whether it confers neuroprotection in vivo. Thus, we sought to investigate the effect of adenoviral injection of TIMP-1 or TIMP-2 on the extent of neuronal damage in a mouse model of global ischemia.
We used replication-deficient human adenovirus serotype 5 encoding human TIMP-1 and TIMP-2 (Ad-TIMP-1 and AdTIMP-2) under the control of the cytomegalovirus major immediate-early promoter (CMVIEP) as described previously. 10 RAd60, which was used as a control vector, contained the CMVIEP and polyadenylation signal but did not express a transgene. 6 PFU/ml), indicated that the optimal concentration of virus to effect transfection of the striatum with minimal toxicity was 10 7 PFU/ml. Similarly, the a b Figure 1 An illustrative example of widespread viral transfection after intrastriatal injection of 0.5 ml 10 7 PFU/ml RAd-lacZ in C57BL/6J mice is shown. These preliminary experiments were conducted to determine the extent and distribution of viral expression using RAd35, which expresses the bacterial lacZ gene. RAd35 gene transfection was determined using different doses of virus (0.5 ml of 10 9 , 10 8 , 10 7 , 10 6 PFU/ml). Halothane anesthetised C57BL/6J received striatal injections of RAd35 (0.5 ml; 0.1 ml/min). Three days later the animals were transcardially perfused and fixed with 0.1 M phosphate buffered 4% paraformaldehyde, the brains removed from the skull and cut in 3 mm coronal slices. A b-galactosidase activity detection method was employed to detect transgene expression of RAd-lacZ. The blocks were paraffin embedded and 6 mm sections were cut. Sections were counterstained with nuclear fast red. Expression in neurons, glia and vessels was detected by b-galactosidase staining. Analysis of the extent of neuronal transfection indicated that 4075% of neurons were transfected after RAd35 (0.5 ml Tissue around each injection tract was dissected out on ice and each tissue sample frozen in liquid nitrogen and stored at À80 1C. Samples were homogenized in lysis buffer (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 5 mM CaCl 2 , 0.05% BRIJ-35, 1% Triton X-100). After centrifugation, the supernatant was recovered and assayed for total protein concentration using the bicinchoninic acid method (Pierce Biotechnology, Perbio Science UK Ltd, Northumberland, UK). Samples of supernatant (80 mg of total protein) were separated by sodium dodecyl sulphatepolyacrylamide gel electrophoresis. A sample of human amniotic fluid collected at term of pregnancy containing TIMP-1 and TIMP-2 was loaded as a control in each gel. Proteins were transferred to a PVDF membrane (Bio-Rad Laboratories Ltd, Hertfordshire, UK), blocked overnight at 4 1C and incubated with the primary antibodies. Mouse monoclonal antibodies recognizing human TIMP-1 (Calbiochem, Merck Biosciences Ltd, Nottingham, UK) and TIMP-2 (Chemicon Europe, Ltd, Hampshire, UK) were used at a dilution of 1:100 and a mouse monoclonal antibody anti-actin (Sigma-Aldrich Company Ltd, Poole, UK, 1:1000 dilution) was used as control for protein loading. Membranes were then incubated with HRP-conjugated anti-mouse antibodies (Amersham Biosciences, GE Healthcare UK Limited, Bucks, UK; 1:5000 dilution), and developed using the ECL chemiluminescent kit (Amersham Biosciences, GE Healthcare UK Limited, Bucks, UK).
Western blot bands were semi-quantified by computer aided image analysis software (AIS, Interfocus, UK) and the intensity of the bands was expressed in relative optical density (ROD) units. Data are expressed as mean relative optical density7s.e.m.
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optimal interval between viral injection and transgene expression was identified as 3 days. Widespread expression in neurons, glia and vessels was detected by b-galactosidase staining in the caudate nucleus after RAd35 (0.5 ml 10 7 PFU/ml) administration ( Figure 1 ). We measured the levels of TIMP-1 and -2 expression in the striatum 3 days after intrastriatal gene transfer of AdTIMP-1 and AdTIMP-2 by Western blot analysis. Anti-TIMP-1 antibodies recognized a protein band of molecular weight approximately 28 kDa and anti-TIMP-2 antibodies detected a protein band of approximately 21 kDa. The levels of TIMP-1 were markedly higher by approximately fivefold in the group receiving intrastriatal AdTIMP-1 as compared to RAd60 and vehicle. Similarly, the levels of TIMP-2 were approximately 12-fold higher in the mice treated with AdTIMP-2 compared to vehicle or RAd60 treatment (Figure 2 ).
After demonstrating that gene transfer of AdTIMP-1 and AdTIMP-2 to the striatum was effective in producing increased levels of TIMPs, we then investigated whether AdTIMPs would be neuroprotective in a model of global cerebral ischemia. Three days before ischemia, either AdTIMP-1 or AdTIMP-2 or RAd60 were injected into the striatum. Transient global cerebral ischemia was then induced to cause neuronal damage in the striatum, which is maximal at 3 days post-ischemia. The extent of ischemic neuronal damage was quantified in the striatum, the brain region where the extent of neuronal damage was more consistent in this model. The extent of neuronal damage was significantly reduced in AdTIMP-1-transfected mice (1172% neuronal damage, Po0.001) as compared to RAd60 transfection (2673% neuronal damage) or vehicle (2272.2% neuronal damage). Similarly, AdTIMP-2-transfected mice had significantly lower levels of neuronal damage (1372% neuronal damage, Po0.01) as compared to Rad60-transfected mice (2672.3% neuronal damage) or vehicle (2272.2% neuronal damage) (Figure 3 ). There was no significant difference in the extent of neuronal cell death between the vehicle and RAd60-treated mice.
In situ zymography was used to demonstrate differences in gelatinolytic activity in the striatum of ischemic animals pretreated with either control, RAD60 or AdTIMP-1 and AdTIMP-2. Gelatinolytic activity was predominantly cellular and localized to neurons, although activity was also detected within cerebral vessels. Gelatinolytic activity was shown to be reduced in the striatum of ischemic mice pretreated with AdTIMP-1 and AdTIMP-2 as compared to control and Rad60 pretreatment (Figure 4) . In all cases, incubation with phenanthroline reduced the gelatinolytic activity (data not shown), suggesting that it was MMP-related.
Discussion
This study provides the first compelling demonstration that gene transfer of TIMP-1 and TIMP-2 through adenoviral vector-mediated delivery to the mouse brain is effective in producing increased levels of TIMPs, and increased expression of TIMP-1 and TIMP-2 effectively reduces the extent of neuronal damage induced by transient global ischemia.
In the past few years, there has been increasing awareness of the role of exaggerated MMPs expression in the pathogenesis of several central nervous system diseases and its contribution to brain tissue injury. 11 We and others reported an early increase in MMP activity, which precedes neuronal cell death after global ischemia, indicative that MMPs contribute to neuronal injury after ischemia. 2, 4 An early upregulation of MMP expression/ activity, has similarly been described after focal ischemia. 3, 12, 13 Compared to MMPs, the role of their natural inhibitors, TIMPs, after ischemia or brain injury is less clear. By virtue of their ability to limit the extent of injury-induced extracellular proteolysis, TIMPs could attenuate neuronal cell death following cerebral ischemia. Reduction of the neuronal loss associated with excitotoxic/ischemic cell damage has been observed in vitro by adenovirus-mediated expression of TIMP-1 through a mechanism of modulation of calcium influx in neurons. 9 TIMP-1 levels in normal adult rodent brain are Halothane anaesthetised male C57BL/6J mice received bilateral intrastriatal stereotactic injections (0.5 ml; 0.1 ml/min) of AdTIMP-1 (n ¼ 16), AdTIMP-2 (n ¼ 14) or RAd60 (n ¼ 12), or vehicle (PBS in 10% glycerol) (n ¼ 13). The experimenter was blind as to the treatment of the mice. After 72 h, ischemia was induced in the same animals by bilateral common carotid artery occlusion as described previously.
2
After three days reperfusion, the animals were deeply anaesthetised with halothane, transcardially perfused and the brains were fixed with 0.1 M phosphate buffered 4% paraformaldehyde and processed for paraffin embedding. The extent of ischemic damage was assessed in 6 mm sections stained with haematoxylin and eosin (H&E). 2 Brain sections were taken at the level of the injection site and ischemic neurons were counted by two independent readers, blinded to the treatment in the caudate nucleus. Morphologically normal and ischemic neurons were counted on H&E-stained sections at Â 400 magnification using a stratified random sampling system, excluding the injection area. Within the same defined area (5 mm 2 on a 100-mm 2 grid within the microscope-eyepiece), the number of normal and ischemic neurons were counted in six randomly sampled areas of the striatum at the level of the injection site (excluding the needle track) on three sections of the striatum. The percentage of ischemic neurons was determined in each single hemisphere. Statistical differences in the percentage of ischemic damage was conducted using one-way analysis of variance (ANOVA) with post-hoc Student's t-test with Bonferroni correction for multiple comparisons. The extent of neuronal damage is not statistically different between the vehicle treated and Rad60 treated mice. Neuronal damage is significantly reduced with intrastriatal injection of adenovirus expressing recombinant TIMP-1 and TIMP-2 compared to Rad60 treated mice and compared to vehicle, **Po0.01, ***Po0.001. Data are mean7s.e.m. One way ANOVA (overall significance Po0.001) with post-hoc Student's t-test with Bonferroni correction for multiple comparisons.
Gene transfer of TIMP confers neuroprotection S Magnoni et al very low and although its expression may be induced early after focal and global ischemia, this may be still inadequate to prevent an exaggerated MMP activity and brain cell death. [13] [14] [15] [16] Interestingly, Rivera et al.
14 reported an induction of TIMP-1 expression after global ischemia, which was time, cellular and spatial-dependent. Early after the ischemic insult TIMP-1 expression was increased in regions resistant to the injury, whereas at a late point intense and persistent expression was detected in areas with a great potential for neurogenesis after ischemic damage. These findings suggest that TIMP-1 might either prevent cell death or modulate repair mechanisms after acute brain injury, depending on the timing of expression, the regions and the cellular source where expression occurs. TIMP-2 is clearly detected in basal conditions in brain tissue and its induction has been described several days after ischemia. 13 Rosenberg et al. 17 showed that TIMP-2 administration reduces proteolytic opening of the blood-brain barrier and hemorrhage caused by intracerebral injection of MMP-2 in rats. More recently, data from TIMP-2 knockouts indicate that TIMP-2 promotes neuronal differentiation in the developing nervous system, in an MMP-independent manner. 18 Whether TIMP-2 may play a role in the adult brain's ability to generate new neurons in response to injury is uncertain at the moment, but this hypothesis supports the possibility that even TIMP-2 could be used therapeutically.
The present study provides clear evidence of neuroprotection of TIMP-1 and TIMP-2 overexpression after ischemic injury, but limited insight into the mechanisms. The main function of TIMPs is to inhibit MMPs activity. As MMP activity contributes to the damage that occurs after cerebral ischemia, TIMP neuroprotection may occur via MMP inhibition. However, other mechanisms might play a more crucial role. TIMPs have a wide variety of functions, such as cell growth-promoting properties and cell survival-modulating mechanisms. 7, 19 Although the receptors have not yet been identified, there is increasing evidence that these functions of TIMP-1 and TIMP-2 are mediated through intracellular signal pathways involving the mitogenactivated protein kinases (MAPs) and protein kinase A (PKA). 20 These kinases have a crucial role in signal transduction from the cell surface to the nucleus, and regulate a number of other downstream proteins and enzymes, like ion channels and transcription factors. MAPs and PKA are also believed to regulate cell death and survival and to be involved in the pathophysiology of cerebral ischemia. 21, 22 In conclusion, the results of this study provide the first evidence that gene transfer of TIMP-1 and TIMP-2 is possible through adenoviral vector-mediated delivery to the mouse brain. Moreover, the study indicates a therapeutic potential of gene transfer of TIMP-1 and TIMP-2 in cerebral ischemia.
Control Rad60
AdTIMP-1 AdTIMP-2 Figure 4 Effect of intrastriatal pre-treatment with AdTIMP-1 (n ¼ 4), AdTIMP-2 (n ¼ 4), RAd60 (n ¼ 4) or vehicle control (n ¼ 4) on gelatinolytic activity determined three days after ischemia using in situ zymography. Representative images of gelatinolytic activity in the striatum are shown from a vehicle control, RAd60, AdTIMP-1, or AdTIMP-2 treated mouse. The injection site is indicated by an arrow. Gelatinolytic activity is predominantly neuronal and is similar with control and RAd60 treatment. In contrast, there is a reduction in activity with AdTIMP-1 and AdTIMP-2 treatment. Frozen 20 mm cryostat brain sections were incubated overnight at room temperature in a humidified dark chamber with 20 mg/ml FITC-conjugated DQ-gelatin (Molecular Probes, Eugene, USA) dissolved in developing buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 5 mM CaCl 2 , 0.2 mM sodium azide). Cleavage of the substrate by proteinases results in unblocking of quenched fluorescence and in an increase in fluorescence intensity. Sections were washed in PBS, fixed with 4% paraformaldehyde and mounted with hard-set Vectashield mounting medium (Vector Laboratories Ltd, Peterborough, UK). Some sections were also incubated with phenanthroline, a broad spectrum MMP inhibitor (Sigma-Aldrich Company Ltd, Poole, UK). Sections were examined with a confocal microscope (Bio-Rad Laboratories Ltd, Hertfordshire, UK).
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